

1 **Minutes**  
2 **Meeting of the Toxicology Subcommittee**  
3 **of the Scientific Advisory Committee**  
4 **Department of Forensic Science**  
5 **October 7, 2025**  
6 **All-Virtual Meeting**  
7

8 **Subcommittee Members Present**

9 Randall E. Beaty

10 Marc A. LeBeau, Ph.D., *Chair*

11 Richard P. Meyers  
12

13 **Staff Members Present**

14 Mason Byrd, Chief Deputy Director

15 James W. Hutchings, Ph.D., Toxicology Program Manager

16 Linda C. Jackson, Director

17 Amy Jenkins, Department Counsel

18 Alka B. Lohmann, Director of Technical Services

19 Scott Maye, Central Laboratory Director

20 Kevin Patrick, Western Laboratory Director

21 Farryl Sorokin, Secretary to the Scientific Advisory Committee

22 Elise Stroble, Grants and Administration Program Manager

23 Rebecca Wagner, Ph.D., Chemistry Research Section Supervisor  
24

25 **Call to Order by Subcommittee Chair**

26 Chief Deputy Director Mason Byrd announced that a quorum of the Subcommittee was present.  
27

28 Chairman LeBeau called the meeting of the Toxicology Subcommittee (Subcommittee) to order  
29 at 9:49 a.m. He reminded members to speak clearly and to keep their cameras on throughout the  
30 meeting.  
31

32 **Adoption of Agenda**

33 Chairman LeBeau advised that the first order of business was the adoption of the draft agenda for  
34 the meeting and noted that the agenda was previously shared with the Subcommittee members by  
35 Ms. Sorokin. Mr. Beaty made a motion to adopt the agenda, which was seconded and passed by  
36 unanimous vote of the Subcommittee.  
37

38 **Adoption of Draft Minutes from the April 22, 2025 Subcommittee Meeting**

39 Chairman LeBeau noted that the draft minutes from the April 22, 2025 meeting of the  
40 Subcommittee were previously shared and asked if there were any proposed changes. Being none,  
41 Chairman LeBeau asked for a motion to approve the minutes. Mr. Beaty made a motion that the  
42 minutes be approved, which was seconded and adopted by unanimous vote.  
43

44 **Discussion of Validation Plans**

45 In advance of the meeting, the members of the Subcommittee were provided with copies of four  
46 validation plans for the following methods:

47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90

- *Validation Plan – Addition of Novel Psychoactive Substances to the Amphetamines, Phentermine, and Designer Stimulants Quantitation and Confirmation by LCMSMS Method.*
- *Validation Plan – Validation of Volatiles Quantitation and Confirmation by Headspace Dual Column Gas Chromatography Flame Ionization Detection (GC-FID).*
- *Validation Plan – Utilization of a Circulating Bath in the Amphetamines, Phentermine, and Designer Stimulants Quantitation and Confirmation by LCMSMS Method.*
- *Validation Plan – Validation for the Addition of Seven Novel Benzodiazepines.*

Dr. Wagner provided an overview of each of the validation plans. Following her presentation about the addition of novel psychoactive substances, there was some discussion around the concentrations being evaluated.

Following Dr. Wagner’s presentation on utilizing a circulating bath, questions were raised about the method and potential loss of matrices and the number of samples for one experiment, which were addressed by Dr. Hutchings and Dr. Wagner. The Committee suggested that the plan be modified to increase the number of samples for one experiment, and DFS agreed to the change.

After the discussion period, Chairman LeBeau asked for a motion to approve the validation plan for *Addition of Novel Psychoactive Substances to the Amphetamines, Phentermine, and Designer Stimulants Quantitation and Confirmation by LCMSMS Method*. Mr. Beaty made a motion to approve the validation plan, which was seconded and passed by unanimous vote of the Subcommittee.

He then asked for a motion to approve the plan for *Validation of Volatiles Quantitation and Confirmation by Headspace Dual Column Gas Chromatography Flame Ionization Detection (GC-FID)*. Mr. Beaty made a motion to approve the plan, which was seconded and passed by unanimous vote of the Subcommittee.

He then asked for a motion to approve the validation plan for *Utilization of a Circulating Bath in the Amphetamines, Phentermine, and Designer Stimulants Quantitation and Confirmation by LCMSMS Method*, with the agreed upon modifications that DFS will make to the plan. Mr. Meyers made a motion to approve the plan with the agreed upon modifications, which was seconded and passed by unanimous vote of the Subcommittee.

He then asked for a motion to approve the plan for *Validation for the Addition of Seven Novel Benzodiazepines*. Mr. Meyers made a motion to approve the plan, which was seconded and passed by unanimous vote of the Subcommittee.

**Public Comment**

An opportunity for public comment was provided. No members of the public commented.

**Adjournment**

91 Chairman LeBeau asked for a motion to adjourn the meeting. Mr. Meyers made a motion to  
92 adjourn the meeting, which was seconded and passed by unanimous vote of the Subcommittee.  
93 The meeting adjourned at 10:13 a.m.